Differential effects of lipid-lowering agents on human cholinesterases

S Darvesh, E Martin, R Walsh, K Rockwood - Clinical Biochemistry, 2004 - Elsevier
Objectives: Epidemiologic reports indicate that lipid-lowering agents (LLAs) protect against
dementia. We hypothesized that LLAs might affect cholinergic systems. The effects of LLAs …

[PDF][PDF] Differential effects of statins and alendronate on cholinesterases in serum and brain of rats.

L Cibičková, V Palička, N Cibiček… - Physiological …, 2007 - biomed.cas.cz
Acetylcholinesterase (AChE) inhibitors represent standard treatment of Alzheimers disease.
Cholesterol plays an important role in Alzheimers disease development. Because …

Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease

I Masse, R Bordet, D Deplanque, A Al Khedr… - Journal of Neurology …, 2005 - jnnp.bmj.com
Background: Data from epidemiological studies and animal models imply that disturbances
in cholesterol metabolism are linked to Alzheimer's disease susceptibility. Lipid lowering …

The risk of dementia in relation to statins and other lipid lowering agents

K Rockwood, S Darvesh - Neurological research, 2003 - Taylor & Francis
Recent epidemiological reports suggest that statins, and possibly other lipid lowering
agents, might be protective for Alzheimer disease, and for other types of dementia …

The Atorvastatin/Donepezil in Alzheimer's disease study (LEADe): design and baseline characteristics

RW Jones, M Kivipelto, H Feldman, L Sparks… - Alzheimer's & …, 2008 - Elsevier
BACKGROUND: Growing evidence suggests that elevated cholesterol levels in mid-life are
associated with increased risk of developing Alzheimer's disease (AD), and that statins …

Increased serum butyrylcholinesterase activity in type IIb hyperlipidaemic patients

J Kálmán, A Juhász, Z Rakonczay, G Ábrahám, M Zana… - Life Sciences, 2004 - Elsevier
The inheritance of the apolipoprotein E4 (APOE4) allele has been shown to increase the
plasma cholesterol level, but little information is as concerns the association of the APOE …

Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people

K Rockwood, S Kirkland, DB Hogan… - Archives of …, 2002 - jamanetwork.com
Background Recent reports suggest a possibly protective effect for statins in patients with
Alzheimer disease. This association could be due to indication bias, ie, people who elect to …

Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease

B Borroni, C Pettenati, T Bordonali, N Akkawi… - Neuroscience …, 2003 - Elsevier
The clinical, genetic or biological variables which regulate long-term efficacy of
cholinesterase inhibitors (ChEIs) in Alzheimer disease (AD) are still unknown and it is not …

The role of cholesterol and statins in Alzheimer's disease

LJ Miller, R Chacko - Annals of Pharmacotherapy, 2004 - journals.sagepub.com
OBJECTIVE: To briefly discuss the impact of elevated total and low-density-lipoprotein
cholesterol levels, as well as the potential relationship of hydroxymethylglutaryl coenzyme A …

Lipid lowering agents, cognitive decline, and dementia: the three-city study

ML Ancelin, I Carrière… - Journal of …, 2012 - content.iospress.com
The aim of this prospective cohort study was to evaluate the effects of lipid lowering agent
(LLA) intake on cognitive function in 6,830 community-dwelling elderly persons. Cognitive …